^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CXCL9 elevation

    i
    Other names: CXCL9, CMK, crg-10, Humig, MIG, SCYB9, Chemokine (C-X-C motif) ligand 9
    Entrez ID:
    4283
    Related biomarkers:
    Expression
    8ms
    C-X-C motif chemokine ligand 9 correlates with favorable prognosis in triple-negative breast cancer by promoting immune cell infiltration. (PubMed, Mol Cancer Ther)
    The analyses from TCGA cohort (n=138) showed that elevated CXCL9 expression correlated with increased infiltration of B-cells, macrophages, natural killer cells, monocytes and increased expression of immune checkpoint molecules and other CXCL family members, including CXCL10 and CXCL11. These findings confirm the regulatory role of CXCL9 in antitumor immunity and suggest a potential role in treatments involving immune-checkpoint blockade.
    Journal • PD(L)-1 Biomarker • IO biomarker • Immune cell
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • CD4 (CD4 Molecule) • CXCL11 (C-X-C Motif Chemokine Ligand 11)
    |
    PD-L1 expression • CXCL9 expression • CXCL9 elevation
    2years
    Essential chemokine score as a potential surrogate for immune checkpoint therapy in pan cancer (AACR 2022)
    The patients in the scoreHigh group enjoyed a significantly longer PFS than those in the scoreLow group (p = 0.0179 and p = 0.0229, respectively). Our findings suggest that CXCL9/10/11 score can serve as a single, universal, and reliable surrogate corresponding to CD274 expression, TMB, and tumor IPs within one variable among many different cancer types, and exhibits a vigorous and attractive potential to predict the therapeutic response to anti-PD-1 therapy in patients.
    Tumor Mutational Burden • PD(L)-1 Biomarker • IO biomarker • Pan tumor
    |
    PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • CXCL9 (Chemokine (C-X-C motif) ligand 9)
    |
    PD-L1 expression • CXCL9 elevation
    over2years
    MCT4 inhibition potentiates hepatocellular carcinoma immunotherapy via enhancing T cell infiltration and immune attack. (PubMed, Hepatology)
    Our results revealed that lactate exportation by MCT4 has a tumor-intrinsic function in generating an immunosuppressive HCC environment and demonstrated the proof of the concept of targeting MCT4 in tailoring HCC immunotherapeutic approaches.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CXCL9 (Chemokine (C-X-C motif) ligand 9)
    |
    CXCL9 elevation
    |
    Loqtorzi (toripalimab-tpzi)